Saverio C.
- Country
- Italy
- Department
- Medical Oncology
Research Overview
- Phase 2 Randomized Trial of Durvalumab Followed by Chemotherapy Versus Chemotherapy Followed by Durvalumab in Elderly Patients with Advanced NSCLC
- Phase II Multicenter Single-Arm Study of Durvalumab with Carboplatin or Cisplatin and Etoposide in First-Line Treatment of Extensive Stage Extrapulmonary Small Cell Carcinoma
- Comparative Evaluation of Giredestrant and Triptorelin Versus Anastrozole and Triptorelin in Premenopausal ER-Positive/HER2-Negative Early Breast Cancer
Data & Insights
Has run more than one trial at 165 of 380 partner sites.
Specializations
Breast Cancer Research
Specializes in investigating targeted therapies for various breast cancer subtypes, with particular focus on HER2-positive and hormone receptor-positive breast cancers.
- Early-stage breast cancer treatment strategies
- Triple-negative breast cancer interventions
- Hormone therapy optimization
Explores innovative treatment approaches including neoadjuvant therapies and biomarker-driven interventions.
Colorectal Cancer Studies
Conducts research on advanced treatment strategies for metastatic colorectal cancer, with emphasis on targeted therapies for patients with specific genetic profiles.
- RAS/BRAF wild-type treatments
- Sequential therapy approaches
- Biomarker-driven treatments
Focuses on developing personalized treatment sequences for improved patient outcomes.
Gynecologic Oncology
Leads investigations in ovarian cancer and related gynecologic malignancies, particularly focusing on novel therapeutic approaches and maintenance treatments.
- Advanced ovarian cancer therapies
- BRCA-related studies
- Peritoneal cancer research
Investigates targeted therapies and molecular-based treatment strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.